ClinicalTrials.gg
RecruitingNCT07266428Updated Nov 10, 2026

A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors

A Phase 1/2 interventional study of OTP-01 in Advanced Solid Tumors, sponsored by Ottimo Pharma Limited. Recruiting at 23 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Ottimo Pharma Limited · Phase 1/2, Interventional, and Other

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.
Updated Nov 10, 20269 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
170
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The main goals of this clinical trial are to find out what the best dose of the study drug, OTP-01, is for patients with solid tumors through understanding how it is tolerated and any side effects that it may cause. The trial will also see if OTP-01 causes tumors to shrink and how the body processes OTP-01 by measuring drug levels in the blood.

The main questions this study aims to answer are:

  • What is the recommended dose of OTP-01 for adults with solid tumors?
  • Is OTP-01 safe and tolerable?
  • Does OTP-01 reduce tumor growth?

Participants will:

  • Receive OTP-01 through an infusion into a vein. Doses will be spaced out and never more than once a week.
  • Have blood tests to evaluate safety and drug levels of OTP-01. These will be done often at first and then less frequently as treatment continues.
  • Have radiographic scans of their tumor at baseline and during the study at regular intervals.
  • Have the choice to have an optional tumor biopsy before and after treatment to help researchers understand how OTP-01 affects cancer and the immune system. These biopsies are voluntary and will not affect participation in the study.
02

Conditions studied

  • Advanced Solid Tumors

Keywords

  • advanced solid tumors
03

In context

Lead sponsor

This is the only study on the registry with Ottimo Pharma Limited as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. or cytologically confirmed advanced (incurable, recurrent, unresectable, or ) solid tumors.

    1. For dose escalation cohort patients: patients must have a tumor type as defined in the protocol. Patients will have progression on or after or intolerance to most recent systemic therapy. Patients must have received approved standard therapy that is available to the patient that is known to confer clinical benefit, unless this therapy is , intolerable to the patient, or is declined by the patient. The reason for treatment decline must be clearly documented in the medical record.
    2. For backfill cohorts: patients must have a tumor type as defined in the protocol. If patients decline an available standard therapeutic regimen known to confer benefit to enroll on this study, the discussion must be clearly documented in the medical record.
  2. per v1.1. Additionally, patients with breast or ovarian cancer with non-measurable, evaluable disease are eligible.
  3. performance status 0-1.
  4. of at least 3 months.
  5. Willing to provide a pretreatment tumor sample (either an or a sample obtained by pretreatment biopsy).
  6. All toxicity resulting from prior cancer therapies must have resolved to v5.0 ≤ Grade 1 or pre-therapy baseline with the exception of alopecia or ≤ Grade 2 neuropathy.
  7. Adequate hematological, renal, and hepatic function.
  8. Other protocol-defined inclusion criteria apply.

Exclusion criteria

Exclusion Criteria:

  1. Receiving systemic at prednisone-equivalent dose of > 10 mg/day within 4 weeks prior to signing consent. Chronic systemic corticosteroid therapy for physiologic replacement (≤ 10 mg/day of prednisone equivalents) and the use of non-systemic corticosteroids (e.g., inhaled, topical, intra-nasal, intra-articular, or ophthalmic) are permitted
  2. History of Grade 4 allergic or anaphylactic reaction to prior monoclonal antibody therapy or allergic reaction to any within the product
  3. History of toxicity requiring permanent discontinuation of prior cancer immunotherapy
  4. Have an active disease that has required systemic treatment in past 2 years (replacement therapy is not considered a form of systemic treatment)
  5. History of organ or stem cell transplant or need for treatment
  6. Have proteinuria > 2 + (within 7 days prior to initiation of study treatment).
  7. Received any chemotherapy, immunotherapy or investigational anticancer therapy within 3 weeks or 5 half-lives (whichever is shorter; minimum of 2 weeks) prior to first dose of study drug
  8. Definitive radiotherapy within 6 weeks and palliative radiation within 2 weeks prior to the first dose of study drug. If previously irradiated, lesions must have demonstrated clear-cut progression prior to being eligible for evaluation as target lesions
  9. Other protocol and subprotocol-defined exclusion criteria apply
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
170 participants (estimated)

Study arms

  • Experimental
    Monotherapy Dose Escalation with Backfill

    Drug: OTP-01

  • Experimental
    Monotherapy Dose Expansion

    Drug: OTP-01

Interventions

  • DrugOTP-01

    Intravenous (IV) Infusion

06

What researchers measure

Primary outcomes

  1. Phase 1 and Phase 2A: Frequency and Severity of adverse events (AEs) and serious adverse events (SAEs)

    Time frame: C1D1 through EoT (up to 36 months)

  2. Phase 2A - Progression Free Survival (PFS)

    Time frame: C1D1 through EoT (up to 36 months)

  3. Phase 2A - Disease Control Rate (DCR)

    Time frame: C1D1 through EoT (up to 36 months)

  4. Phase 2A - Duration of Response (DOR)

    Time frame: C1D1 through EoT (up to 36 months)

  5. Phase 2A - Objective Response Rate (ORR)

    Time frame: C1D1 through EoT (up to 36 months)

Secondary outcomes

  1. Phase 1 and Phase 2A - plasma concentrations of OTP-01

    As a function of time post-dosing

    Time frame: C1D1 through EOT (up to 36 months)

  2. Phase 1 and Phase 2A - Area under the curve [AUC]

    Time frame: C1D1 through EOT (up to 36 months)

  3. Phase 1 and Phase 2A - Maximum plasma concentration [Cmax]

    Time frame: C1D1 through EOT (up to 36 months)

  4. Phase 1 and Phase 2A - Minimum plasma concentration [Cmin]

    Time frame: C1D1 through EOT (up to 36 months)

  5. Phase 1 and Phase 2A - Time of maximum concentration [Tmax]

    Time frame: C1D1 through EOT (up to 36 months)

  6. Phase 1 and Phase 2A - Half-life [t1/2]

    Time frame: C1D1 through EOT (up to 36 months)

  7. Phase 1 and Phase 2A - Clearance [CL]

    Time frame: C1D1 through EOT (up to 36 months)

  8. Phase 1 - Progression Free Survival (PFS)

    Time frame: C1D1 through EoT (up to 36 months)

  9. Phase 1 - Disease Control Rate (DCR)

    Time frame: C1D1 through EoT (up to 36 months)

  10. Phase 1 - Duration of Response (DOR)

    Time frame: C1D1 through EoT (up to 36 months)

  11. Phase 1 - Objective Response Rate (ORR)

    Time frame: C1D1 through EoT (up to 36 months)

07

Study locations

23 of 23 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2025 (actual). Primary completion is estimated for Dec 2028, 36 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2025
First posted
Dec 5, 2025
StartActual
Dec 17, 2025
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2028
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
9 sites added
Show 9 added (5 Spain, 3 Brazil, 1 Turkey (Türkiye))
  • Oncosite - Centro de Pesquisa Clinica Em Oncologia · Ijuí, Brazil
  • Instituto do Cancer do Estado de São Paulo (ICESP) · São Paulo, Brazil
  • Oncostar · São Paulo, Brazil
  • NEXT Oncology Barcelona · Barcelona, Spain
  • NEXT Oncology Madrid · Madrid, Spain
  • START - Rioja · Rioja, Spain
  • Ankara Bilkent City Hospital · Ankara, Turkey (Türkiye)
  • Hospital Universitario Vall d'Hebron · Barcelona, Spain
  • Hospital Universitario 12 de Octubre · Madrid, Spain
across 2 updates, Oct 9, 2026 – Nov 10, 2026
Show all 2 updates
  1. Nov 10, 2026
    2 sites added
    Show 2 added (2 Spain)
    • Hospital Universitario Vall d'Hebron · Barcelona, Spain
    • Hospital Universitario 12 de Octubre · Madrid, Spain
    + 1 other change: verification date
  2. Oct 9, 2026
    7 sites added
    Show 7 added (3 Brazil, 3 Spain, 1 Turkey (Türkiye))
    • Oncosite - Centro de Pesquisa Clinica Em Oncologia · Ijuí, Brazil
    • Instituto do Cancer do Estado de São Paulo (ICESP) · São Paulo, Brazil
    • Oncostar · São Paulo, Brazil
    • NEXT Oncology Barcelona · Barcelona, Spain
    • NEXT Oncology Madrid · Madrid, Spain
    • START - Rioja · Rioja, Spain
    • Ankara Bilkent City Hospital · Ankara, Turkey (Türkiye)
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07266428
Lead sponsor
Ottimo Pharma Limited
Responsible party
Sponsor
First posted
Dec 5, 2025
Start date
Dec 17, 2025
Primary completion
Dec 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Nov 10, 2026

Study contacts

Katherine Bell-McGuinn
study director · Ottimo Pharma Limited

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion